Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

A New Approach to Target An ‘Undruggable’ Prostate Cancer Driver

By University of Michigan School of Medicine | March 30, 2017

New research suggests a novel strategy to target a genetic anomaly that occurs in half of all prostate cancers.

When the genes TMPRSS2 and ERG relocate on a chromosome and fuse together, it’s an on-switch for prostate cancer development. But ERG has proven to be a challenging target for the type of small-molecule inhibitors that have had recent successes in treating cancer.

Now, researchers from the University of Michigan Comprehensive Cancer Center have targeted ERG using large molecule peptides. Studies in cell lines and animal models suggest this approach can effectively target and degrade the ERG fusion with little impact on regular cell function. Their findings are published in Cancer Cell.

“Targeting this gene fusion product has been a major challenge. We had to approach this through a different angle,” says senior study author Arul M. Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology and S.P. Hicks Professor of Pathology at Michigan Medicine.

The researchers identified a panel of peptides that interacted specifically with the ERG protein. They tested the panel in cell lines harboring the gene fusion and found the peptides disrupted ERG function. In cells without the gene fusion, the peptides had little or no impact on gene expression.

They also looked at how the peptides impacted other biological processes regulated by ERG. These tests suggested that the peptides very specifically target the gene fusion without affecting normal cellular functions.

One problem was that peptides degraded quickly, not lasting long enough to travel to the desired target. So the researchers generated mirror images of the peptides. These peptidomimetics avoid the machinery that causes degradation of normal peptides in the body, leading to longer stability.

Tests in animal models showed the peptidomimetics reduced the growth of prostate tumors that harbored the ERG fusion. After extended treatment, more than a third of the mouse tumors showed no signs of recurrence a month later.

“This is an example of how we can deliver precision therapy for prostate cancer: Only patients who have the ERG gene fusion would be matched with this agent. But it’s useful because the ERG fusion is so prevalent,” Chinnaiyan says.

One drawback to the peptide approach is that large molecules like this can’t slip past the cell membrane. That means that the peptides need to modified in some way or be delivered across the cell membrane. Small molecules are the preferred target for drug development because they can get inside of cells and bind to their target more easily.

Chinnaiyan’s team will next work to create a three-dimensional outline of how the peptides bind to ERG in the hopes of turning this into a small molecule to inhibit ERG. In parallel, researchers will focus on making the peptidomimetics work better, with more potency in degrading the target.

“This research will potentially develop a new targeted therapy for prostate cancer while we will simultaneously gain knowledge on the inhibition of a very complex gene that drives cancer,” said Dr. Howard R. Soule, executive vice president and chief science officer of the Prostate Cancer Foundation, which funded this work.


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE